Gland Pharma Dividends and Buybacks
Dividend criteria checks 4/6
Gland Pharma is a dividend paying company with a current yield of 1.23% that is well covered by earnings.
Key information
1.2%
Dividend yield
-0.01%
Buyback Yield
| Total Shareholder Yield | 1.2% |
| Future Dividend Yield | 0.4% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹20.000 |
| Payout ratio | 46% |
Recent dividend and buyback updates
No updates
Recent updates
Gland Pharma Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next
Nov 07
Gland Pharma Limited (NSE:GLAND) Shares Could Be 23% Above Their Intrinsic Value Estimate
Oct 26Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet
Oct 01Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)
Sep 05Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 09Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?
Jun 22Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts
May 25Is Gland Pharma (NSE:GLAND) A Risky Investment?
Mar 19Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion
Feb 16Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher
May 20Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 07Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers
Jul 22Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?
Jul 14Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?
Feb 08Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Too early to tell whether GLAND's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if GLAND's dividend payments are increasing as they only just started paying a dividend.
Dividend Yield vs Market
| Gland Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GLAND) | 1.2% |
| Market Bottom 25% (IN) | 0.3% |
| Market Top 25% (IN) | 1.2% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (GLAND) (up to 3 years) | 0.4% |
Notable Dividend: GLAND's dividend (1.23%) is higher than the bottom 25% of dividend payers in the Indian market (0.25%).
High Dividend: GLAND's dividend (1.23%) is in the top 25% of dividend payers in the Indian market (1.18%)
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (45.6%), GLAND's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (40.2%), GLAND's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 11:36 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gland Pharma Limited is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Neha Manpuria | BofA Global Research |